Article Sidebar

Submitted
December 21, 2020
Accepted
October 4, 2021
Published
December 11, 2021
Download
PDF XML
Statistic
Read Counter : 992 Download : 392

Downloads

Download data is not yet available.

Abstract

Neuroinfectious diseases continue to have a profound public health impact, particularly in resource-limited settings. Here we summarize the new research into pathophysiology, diagnosis, and treatment modalities for some of the most frequent and lethal infections affecting the central nervous system, including tuberculosis, malaria, and arboviral infections. Implementation of clinical trials targeting neuroinfectious diseases in resource-limited settings has unique challenges not found when identical research is performed in resource-rich areas. Travel, communications, and technology have improved the mobility of populations worldwide. Immigration and increased international travel make it likely that clinicians worldwide will see patients affected by infectious diseases such as malaria, tuberculosis, zika, dengue, chikungunya, and Ebola. Such infections may have devastating consequences for both the individual and the society, particularly if clinicians are not familiar with disease presentation and treatment.

Introduction

Central nervous system (CNS) infections are a global problem with profound public health impact, contributing to both the mortality and neurological morbidity in survivors. The Global Burden of Disease network estimated that in the year 2010, of all deaths in children 1–4 years old, meningitis and encephalitis caused 4·2%, acquired immunodeficiency syndrome 5%, malaria 21%, and tuberculosis 1.3% [1]. Causal pathogens vary by geographic regions, vaccination coverage, route of pathogen acquisition, as well as the patient’s age and co-morbidities [2,3]. Though the estimates of disease incidence and prevalence are publicly available, the actual burden of CNS infections in low and middle-income countries (LMICs) may be underestimated due to the relative lack of surveillance systems and diagnostic modalities [4].

Travel and improvements in communications and technology have improved the worldwide mobility of populations. Infectious diseases previously limited to specific geographic areas are no longer limited to the places where prevalence is highest. With international travel, patients affected by infectious diseases such as malaria, tuberculosis, zika, dengue, chikungunya and Ebola can be encountered anywhere in the world. These infections may have devastating consequences for both the individual and society, especially if clinicians are unfamiliar with disease manifestations and treatment.

CNS tuberculosis: recent concepts in diagnosis and treatment

According to 2018 World Health Organisation (WHO) estimates, there are one million children worldwide who are younger than 15 years old with tuberculosis; nearly one-fourth die annually. CNS tuberculosis, including tuberculous meningitis (TBM) and tuberculomas, accounts for 5–10% of all clinical presentations in children. Children with TBM have a 19% risk of death (95% confidence interval [CI] 14.0–26.1); the probabil- ity of survival without neurological sequelae is 36.7% (95% CI 27.9–46.4) [5]. Delay in treatment initiation is the highest risk factor for mortality. Unfortunately, due to a lack of universally available and sensitive diagnostic tests, an early diagnosis is frequently challenging. Even if a diagnosis is made in a timely fashion, the duration of anti-tuberculous therapy (ATT) for children with TBM is controversial.

The diagnosis of TBM relies on the clinical, cerebrospinal fluid (CSF) and neuroimaging features. The presence of non-CNS tuberculosis in the patient or family members is an essential epidemiological risk factor for the diagnosis. Fever is the most common sign (60–95%), followed by seizures (50%) and cranial nerve deficits (30–50%) [6]. Making a clinical diagnosis may be challenging, as young children frequently present with non-specific symptoms of poor weight gain, low-grade fever and irritability. Though the average duration between symptom onset and initial presentation at a healthcare facility for those with TBM is 5–30 days, many children do not arrive until comatose or with other classic neurological findings [7].

Neuroimaging, when available, is especially important for early diagnosis. Though computed tomography is more common in resource-poor settings, magnetic resonance imaging (MRI) is more sensitive (Figure 1) [8]. In addition to neuroimaging, other supporting or diagnostic laboratory tests may help the clinician to establish a diagnosis (Table 1). The poor sensitivity of nucleic acid amplification-based testing is believed to be due to the paucibacillary nature of TBM in children, the presence of amplification inhibitors in the CSF, and challenges with cell lysis in biological specimens due to the impermeable cell wall of M. tuberculosis[9].

Figure 1.Contrast-enhanced magnetic resonance imaging of the brain in a child with tuberculous meningitis showing exudates in the basal cisterns and leptomeningeal enhancement in the axial section.

A recent meta-analysis concluded that nucleic acid amplification-based tests’ diagnostic accuracy is currently insufficient for them to replace culture as the only diagnostic modality [10]. A Cochrane review showed a pooled sensitivity of 54% and specificity of 94% for Xpert MTB/RIF (Mycobacterium tuberculosis/rifampin) [11]. The authors concluded that in children with presumed TBM, treatment decisions should be based on the entirety of clinical information. Treatment initiation should not be withheld based solely on a pending or negative Xpert MTB/RIF result. WHO guidelines for tuberculosis state that commercial serodiagnostics should not be used in children suspected of active pulmonary or extrapulmonary TB, irrespective of their human immunodeficiency virus (HIV) status. Moreover, in LMICs, interferon-gamma release assays should not replace tuberculin skin testing to diagnose latent or active tuberculosis infection in children (irrespective of HIV status). Due to the high rates of coinfection, routine HIV testing should be offered to all patients with presumptive and diagnosed tuberculosis, including children [12].

Hydrocephalus and/or vascular strokes commonly complicate TBM. In 80% of survivors, communicating hydrocephalus is present, secondary to blockage of CSF resorption in the basal cisterns from inflammatory exudates. Medical and surgical management of secondary intracranial hypertension may include emergency ventricular tap or extra-ventricular drainage, or a more definitive CSF diversion method such as a ventriculoperitoneal shunt [13]. Strokes occur in 15–57% of paediatric TBM patients and are secondary to caseous meningoencephalitis and vasculitis, with or without superimposed vascular thrombosis. Basal ganglia infarction is common due to medial striate, thalamotuberal, and thalamic perforator involvement [14]. A systemic review of 546 patients with TBM evaluated the benefits of aspirin co-administration in the management of TBM [15]. Though the addition of aspirin to the ATT regimens did not significantly reduce mortality, adjunctive aspirin reduced the risk of new CNS infarctions compared to controls (RR = 0.52, 95% CI = 0.29- 0.92) [15]. TBM may be complicated by vision loss secondary to optic atrophy, chiasmal tuberculoma, optico-chiasmal arachnoiditis, cortical blindness, or ethambutol toxicity [16,17]. The spinal form of tuberculosis may manifest as tubercular arachnoiditis, myelitis, acute spinal cord or cauda equina syndromes, an intramedullary spinal tuberculoma, syringomyelia, tuberculous spondylitis (extradural) or Pott’s disease [18,19].

The treatment of paediatric CNS tuberculosis includes acute management of raised intracranial pressure, ATT, corticosteroids, anti-epileptic drugs, management of complications, and optimising nutrition and physiotherapy. The recommended ATT regimen consists of four drugs (isoniazid, rifampicin, pyrazinamide and ethambutol in fixed-dose combination) in the intensive phase for two months, followed by two drugs (isoniazid, rifampicin) in the maintenance phase for ten months. Higher doses of ATT and modified regimens have been recommended, but the duration of ATT must be at least 12 months [12,20,21]. For those with multi-drug resistant disease, the WHO has recently suggested consolidated guidelines for treatment [22]. A recent systematic review of treatment outcomes for children with multi-drug resistant tuberculosis determined a pooled estimate for treatment success of 82% (95% CI 72.5–90.8). When children are treated, outcomes are at least as good as those for adults [23]. Research priorities moving forward should include determining optimal doses and duration of ATT in children with CNS tuberculosis, with or without multi-drug resistance.

HIV coinfection with TBM is associated with an earlier age at disease presentation, CSF neutrophil predominance, reduced meningeal enhancement, reduced odds of secondary hydrocephalus (believed to be secondary to a reduced inflammatory response from impaired cell-mediated immunity), diffuse brain atrophy, and a poorer overall prognosis [24,25]. Immune reconstitution syndromes involving the CNS are common in children in whom antiretroviral therapy is initiated. The recovering immune system mounts an exuberant inflammatory response against mycobacterial antigens, and clinical symptoms usually begin within three weeks of starting antiretroviral therapy [25]. Affected patients undergo a clinical or radiological deterioration after an initial period of clinical improvement on ATT. The recommendation for prevention of TBM-IRIS (immune reconstitution inflammatory syndrome) is to withhold anti-retroviral therapy (ART) until after 4–8 weeks of anti-TB treatment. Management includes simultaneous treatment of TB and HIV, with the regimen determined by CD4 counts. Unfortunately, there is little evidence-based guidance for the management of paradoxical, tuberculosis-related immune reconstitution inflammatory syndromes in children. Corticosteroids are the mainstay of treatment [26]. Interruption of ART may be necessary in life-threatening cases. Anecdotally, thalidomide, mycophenolate, chloroquine and infliximab have been used. Human recombinant interleukin-1 receptor antagonists have been used as steroid-sparing therapy for life-threatening protracted paradoxical inflammation in HIV-associated tuberculosis [27].

In summary, TBM should be considered for any form of meningitis of more than five days duration in endemic settings. Newer molecular tests may aid early diagnosis, but neuroimaging is very helpful in LMICs in making an early diagnosis. At least one year of ATT is indicated in children with TBM, monitoring for complications and considering neuroimaging before stopping ATT.

Cerebral malaria: Recent concepts in diagnosis and treatment The WHO estimated 228 million cases and 405,000 deaths due to malaria worldwide in 2018. Children under five years of age constituted 67% of all malaria deaths. More than 90% of cases and deaths occurred in Africa [28]. Although clinical malaria has decreased by about 37% in the past 20 years, most cases still occur in children aged six months to six years old. Five species of Plasmodium infect humans through the bite of the infected female Anopheles mosquito—Plasmodium falciparum, Plasmodium malariae, Plasmodium vivax, Plasmodium ovale and Plasmodium knowlesi. Of these, P. falciparum is the most common species associated with cerebral malaria (CM). The female mosquito inoculates sporozoites into the human blood, which infect liver cells and subsequently erythrocytes. The erythrocytic stages cause clinical symptoms, while the liver stages are responsible for relapses (P. vivax and P. ovale). Sequestration of parasitised red blood cells in the deep vascular beds of the brain is found in children dying after a clinical diagnosis of CM, and is thought to be the most important pathophysiological process leading to coma and death.

The WHO defines CM as impairment of consciousness (Blantyre coma scale less than three and more than one hour after a clinical seizure), the presence of asexual parasites in the peripheral blood, and the exclusion of other causes of coma [29]. Neurological features may include seizures or agitation [30]. A paradigm shift in the clinical diagnosis of CM was the identification of a malaria-specific retinopathy identified at the bedside with a combination of direct and indirect ophthalmoscopy. Features include whitening in the perimacular and peripheral retina, pale colour of retinal vessels, retinal haemorrhages, without or with papilloedema. Autopsy studies of children dying of CM who had malarial retinopathy (and were diagnosed with retinopathy-positive CM) revealed high levels of sequestration of parasitised erythrocytes in cerebral venules [31]. Retinopathy severity correlates with the degree of sequestration of infected red blood cells in the retina and the brain [32]. In endemic areas, a viral CNS infection may coexist in children with clinical CM and cause diagnostic confusion. A recent study of CSF from 111 children with clinical CM found viral co-infections in 18% of those who were retinopathy-positive, and in 25% of those who were retinopathy-negative [33]. Neither mortality nor neurological morbidity was associated with the presence of a virus (odds ratio = 0.276, 95% CI 0.05–1.36). The authors concluded that viral nucleic acid in the CSF of children with CM may be incidental bystanders, reactivating during acute malaria infection [33].

Observational studies on children with CM reveal that the neurological sequelae are common in survivors, most commonly hemiparesis, vision and hearing impairments, severe motor deficits, ataxia and learning disabilities. A recent metaanalysis of eight studies, enrolling a total of 2005 participants, determined that CM is associated with an increased risk of epilepsy (OR 4.68, 95% CI: 2.52–8.70), intellectual impairment (OR 4.72, 95% CI: 0.78–28.49), neuro disabilities (OR 16.16, 95% CI: 1.34–195.45), and behavioural disorder (OR 8.47, 95% CI: 2.75–26.04) [34]. A quarter of children have a cognitive impairment, which may be detected three to six years after recovery from the index illness. The cognitive impairment includes deficits in executive functioning, processing, memory, language and behaviour.

Currently available diagnostic tests for malaria include microscopy, rapid diagnostic tests, indirect fluorescent antibody test and PCR. Microscopy, using the Romanovsky (Giemsa) stain remains the gold standard for laboratory confirmation of malaria and allows species identification. Rapid diagnostic tests use point of care blood sampling to test for malaria-specific antigens. Negative rapid diagnostic tests should be confirmed with microscopy especially in non-immune travellers where parasitaemia may be extremely low at the time of symptom-onset. The indirect fluorescent antibody test is commonly used for screening of blood donors. PCR testing is currently used for research purposes and is frequently unavailable for routine clinical testing in malaria-endemic areas.

Predictive clinical features of TBM in children
• Duration of symptoms are more than five days: most predictive
• Glasgow coma score is less than 15
• Presence of focal neurological deficits
• Neutrophil count is less than 50% of total white cells
Clinical stages of TBM
Stage I: Lucidity, no focal neurological signs or evidence of hydrocephalus
Stage II: Lethargy, confusion, mild focal signs, such as cranial nerve palsies or hemiparesis
Stage III: Advanced illness with delirium, stupor, coma, seizures, multiple cranial nerve palsies, and/or dense hemiplegia
Extra-cranial markers of disease
• Mantoux test: A positive test identifies exposure to tuberculosis and not active disease; sensitivity 61%, reduced to 34%with HIV coinfection
• Radiological evidence of pulmonary tuberculosis is seen in 60% of children
• History of contact with another tuberculosis patient is present in 30–50% of children
Cerebrospinal fluid examination
• Appearance: transparent or mild xanthochromia
• Total cell counts: 100 and 500 cells per µl
• Lymphocytic predominance (60–85% of cases)
• Early neutrophilic predominance (30–75%)
• CSF opening pressure: more than 25cm water (50% cases)
• Protein: elevated (100–500 mg/dl)
• Glucose: low (absolute value less than 45mg/dl), CSF: blood sugar ratio below 0.5
Microbiological assays
• Smear microscopy: Ziehl Neelsen stain: rapid and economical, sensitivity 10–60%
• Culture: Traditional LJ medium (turnaround time 28-50 days), shorter with Bactec (MGIT960, Radiometric 460) culturemedium
Neuroimaging [30,35,36]
• CT scan: most common neuroimaging modality in resource-limited settings
• Most specific (100%): pre-contrast hyperdensity in basal cisterns
• Most sensitive (89%): basilar enhancement
• Combination of hydrocephalus, infarction, and basilal enhancement is 100% specific
• Bilateral basal ganglia infarcts: highly suggestive of TBM
• Contrast-enhanced MRI: more sensitive, delineates mild basal meningeal enhancement, tuberculomas, miliary leptomeningeal tubercles, opto-chiasmatic arachnoiditis, spinal TB, detection, and localisation of infarct
• Single-photon emission computed tomography (SPECT): evaluates vasculitis due to TBM, reduced blood flow in affectedregions of the brain
• Fluorodeoxyglucose (FDG)-positron emission tomography (PET): increased uptake in focal brain lesions, specifically inthe meninges and cerebellum
• MR angiography: segmental narrowing and irregular beaded appearance, moyamoya syndrome
• Transcranial doppler: real-time information about cerebral blood flow velocities
• MR spectroscopy: prominent lipid peak (representing caseation), slightly increased choline (cellular component), or areduced NAA and creatine peak (partial volume effect)
• Contrast-enhanced FLAIR: for early detection of paradoxical tuberculoma
Molecular analysis of CSF [37-40]
• Nucleic acid amplification tests: sensitivity 56%, specificity 98%
• Yield improved by physical methods of cell lysis, such as shock treatment (freezing and heating) or Triton X 100 treatmentcombined with DNA extraction procedures
• Loop-mediated isothermal amplification (LAMP) assay is a single-tube technique for the amplification of DNA and alow-cost alternative to detect certain diseases: sensitivity 88%, specificity 80% for MTB
• IS6110 (sequences of mycobacterial genome) and Protein b (38 kDa protein product which is specific for MTB complex)-based multiplex polymerase chain reaction (PCR) test: rapid method, sensitivity 77.8 %, specificity 100%
• MTB cell-free DNA in CSF: rapid and accurate, sensitivity 56.5%
• Multiplex PCR: amplify several target genes simultaneously, sensitivity 85%–95%
• CSF Xpert MTB/RIF: test that simultaneously detects MTB by PCR and resistance to RIF in less than two hours
• Xpert Ultra: improved sensitivity but insufficient negative predictive value to exclude TBM
• Xpert MTB/XDR: detects resistance to both first-line and second-line drugs
• GeneXpert Omni: underdevelopment, portable point-of-care diagnostic test
• Truenat ® MTB, Truenat ® MTB Plus, and Truenat ® MTB-Rif Dx: Chip-based, micro real-time PCR assays for diagnosis of TB and rifampicin resistance
Newer tests in the pipeline
• Next-generation sequencing
Biochemical analysis
• CSF adenosine deaminase (ADA)
• Simple, inexpensive, rapid, with a sensitivity of 75–83%, specificity 89–93%
• Cut-off value of 10.5 iu/l
• Values from 1–4 u/l: sensitivity more than 93%, specificity less than 80%, helpful to exclude TBM, between 4 and 8 u/l:insufficient to confirm or exclude TBM, values more than 8 u/l: sensitivity less than 59%, specificity more than 96%36
• ESAT-6 immunostain frequently used in enzyme-linked immunospot assay for detection of active etuberculosis: sensitivity 75%, specificity 90%
• 16 kDa (HspX) antigen: is an immunodominant antigen that is recognised in cases with active tuberculosis by ELISA:sensitivity 43%, specificity 95%
• Lipoarabinomannan ELISA: is a direct antigen-capture ELISA based on the detection of mycobacterial lipoarabinomannan in unprocessed urine, sensitivity 64%, specificity 69%
• TB-ELISPOT: is a T-cell based assay for the detection of infection with MTB, sensitivity 71%, specificity 57%
• CSF interferon gamma release assays: sensitivity 59–84%, specificity 73–89%
• BacT/ALERT : BacT/Alert (Organon Teknika Corp., Durham, N.C.) is an automated microbial detection system based onthe colorimetric detection of CO2 produced by growing microorganisms, sensitivity 25%, specificity 100%
• CSF Antigen detection tests: sensitivity 35–95%, specificity 95–100%
• Tuberculostearic acid on GCMS): sensitivity 80–100%, specificity 80–100%
• Proteomic analysis of CSF: sensitivity 80-100%, specificity 80–100%
TBM, tubercular meningitis; HIV, human immunodeficiency virus; CSF, cerebrospinal fluid; LJ, Lowenstein Jensen; CT, computed tomography; MTB/XDR,multidrug-resistant tuberculosis/extensively drug-resistant; GCMS, gas chromatography mass spectrometry; TB-ELISPOT or T-Spot, enzyme-linked immunospot assay for interferon-γ; ESAT-6, 6 kDa early secretory antigenic target produced by MTB; MTB, Mycobacterium tuberculosis
 Table 1.Table 1. Summary of the diagnostic tests utilised for tuberculosis and tuberculous meningitis [7,8,35]

Anti-malarial therapies have undergone recent advancements, with a shift from quinine or quinidine to artemisinin-based medications. Artemisinins kill parasites in all life stages and is associated with more rapid parasite clearance times. Moreover, treatment with artesunate significantly reduces the risk of death, both in adults (RR 0.61, 95% CI 0.50–0.75) and children (RR 0.76, 95% CI 0.65–0.90), compared to intravenous quinine [41].

Seizures, both clinical and electrographic, are common in children with CM [42]. A previously completed clinical trial of intravenous adjunctive phenobarbitone (compared to placebo) produced a reduction in seizures but increased mortality [43]. A double-blinded, randomised trial of comparing a single intramuscular injection of fosphenytoin with placebo did not show any remarkable difference in preventing seizures and neurological sequelae in children with CM and acute coma [44]. A recently published phase I/II randomised clinical trial of enteral levetiracetam versus intravenous phenobarbital (the standard of care) for children with CM showed equal efficacy (time of electrographic seizures) of the interventions, but a more favourable safety profile for levetiracetam [45]. Pharmacokinetic parameters were comparable to studies of enteral levetiracetam performed in high-income countries (HICs) in children with non-malarial illnesses.

Figure 2.Plain magnetic resonance imaging (MRI) of the brain, sagittal section of the T1-weighted sequence in a child with cerebral malaria showing diffuse brain swelling and incipient uncal herniation.

Thus far, numerous interventional clinical trials of adjunctive therapies for children with CM have been performed with endpoints of death, disability, or both. None of these has shown a clinically meaningful improvement in outcome for participants randomised to the intervention, compared to controls [46]. Recent insights into CM pathogenesis have revealed novel therapeutic targets for rational design of potentially beneficial interventions. Diffuse brain swelling is common in children with CM and is strongly associated with death (Figure 2) [47]. Since many children dying of CM have a pure respiratory arrest, increased intracranial pressure is likely leading to herniation syndromes, compression of the respiratory centres, and apnoea. Mechanical ventilation may help to preserve life while diffuse brain swelling diminishes. Intravenous hypertonic saline may work as an osmotic diuretic, directly decreasing brain swelling. An ongoing Phase III randomised clinical trial is evaluating the effectiveness of mechanical ventilation and hypertonic saline in Malawian children with cerebral malaria at high risk of death (NCT03300648). One-third of the participants will receive treatment as usual, one-third will receive treatment as usual as well as being placed on a mechanical ventilator, and one-third will receive treatment as usual plus intravenous hypertonic saline.

Of particular interest to paediatric neurologists are the neurological syndromes after the clearance of parasitaemia in malaria. These include acute demyelinating encephalomyelitis, postmalaria neurological syndrome (within two months of illness), cerebellar syndrome (onset three to four weeks after the febrile illness), encephalopathy, ataxia, opsoclonus, benign intracranial hypertension, Guillain-Barré syndrome, and myelitis.

Efforts to better understand CM pathogenesis must continue. A better understanding of the processes between the bite of an infective Anopheles mosquito and death or neurological disability may allow for the design of clinical trials to test interventions found to be important in disease pathogenesis. A recent meta-analysis highlighted the importance of timely treatment in preventing severe disease and deaths in malaria [48]. This underscores the need to have prompt access to first-line anti-malarial drugs and early referrals to higher centres for severe cases.

Dengue, zika and chikungunya: acute neuroinfections

Around 3.3 billion people live in the tropics, which constitute half of the world’s population [49,50]. High temperatures and vector abundance make these areas a high-risk area for establishing and spreading arboviral diseases. In the last decades, due to global climate change, many parts of the world outside of tropical areas are becoming ‘tropical regions’ [49]. In tropical regions, over twenty neglected tropical diseases affect over one billion people each year. Many neglected tropical diseases, including dengue, chikungunya and zika, have neurologic consequences.

The term ’arbovirus’ (ar, arthropod; bo, borne) includes several families of RNA viruses spread by arthropod vectors, most commonly mosquitoes, ticks and sand flies. The families of viruses included in the arbovirus group are Flaviviridae, Togaviridae, Bunyaviridae and Reoviridae [51]. Neurotropic arboviruses preferentially infect the neurons in the CNS and belong to several different RNA virus families. Clinically relevant neurotropic arboviruses include flaviviruses (West Nile, St. Louis encephalitis and Japanese encephalitis viruses), bunyaviruses (La Crosse and California encephalitis virus), and New World alphaviruses (eastern, western, and Venezuelan equine encephalitis viruses), and recently zika, dengue and chikungunya viruses [52].

Zika virus infection
• Congenital zika syndrome
• Guillain-Barré syndrome
• Sensory neuropathy
• Encephalitis/meningoencephalitis
• Inflammatory myelitis
• Acute disseminated encephalomyelitis
• Optic neuropathy
• Seizures and epilepsy (epileptic spasms, focal and generalised onset motor seizures, myoclonus)
• Vasculitis and childhood arterial ischaemic stroke
Chikungunya infection
• Meningoencephalitis
• Myelitis
• Guillian Barré syndrome
• Seizures
• Psychosis
• Encephalo-myelo-radiculitis
• Brain stem encephalitis
• External ophthalmoplegia
• Facial palsy, sensorineural deafness
• Optic nerve involvement (papillitis, retrobulbar neuritis, neuroretinitis, optic neuritis)
Dengue virus infection
• Encephalitis
• Encephalopathy
• Meningitis
• Stroke
• Cerebellar syndrome
• Transverse myelitis
• Acute disseminated encephalomyelitis
• Guillain-Barré syndrome
• Myositis
• Hypokalemic paralysis
• Dengue-associated neuritis (such as brachial neuritis, long thoracic nerve palsy, phrenic nervepalsy, abducens nerve palsy and peripheral facial palsy)
 Table 2.Table 2. Common neurological complications of zika, dengue and chikungunya virus infection.

Arbovirus infections are associated with a wide spectrum of neurological manifestations. We review here zika, dengue and chikungunya infections, all of which have rapidly expanded their geographic distribution.

The zika virus is a single-stranded RNA Flavivirus that causes encephalitis and fetal microcephaly and is transmitted by the bite of Aedes mosquitoes. It was first isolated from a rhesus monkey in the Zika forest in Uganda in 1947 and from Aedes africanus mosquitoes in 1948 [53]. In 2007, a zika outbreak in the Yap Islands in the Federated States of Micronesia represented the first time the virus was detected outside Africa and Asia [54]. In February 2016, the WHO declared the zika virus infection a global public health emergency following reports of clusters of microcephaly and other neurological disorders in 2015 in Brazil [55,56]. By 2017, the WHO estimated that nearly 100 million people were infected, including more than one million pregnant women in the Americas, suggesting that tens of thousands of children were at risk for the congenital ZIKV syndrome [57,58]

The acute clinical syndrome resembles dengue or chikungunya. Over the years, zika virus infection has become neuroinvasive with reports of several neurological complications (Table 2) [59]. The underlying pathogenesis may include: direct infection of neural stem cells in the fetal brain; immune response against peripheral myelin and/or axonal components; infection of mature CNS neurons with ensuing cell death and pathogenic transcriptional dysregulation; endothelial injury; or a direct viral inflammatory process in the CNS [60,61]. The initial description of the presumed congenital zika syndrome and congenital microcephaly from Brazil included a facial dysmorphism, cutis gyrata (scalp skin folds, secondary to continued skin growth concurrent with cerebral malformations), preservation of primitive reflexes, hypertonia, hyperreflexia, irritability, tremors, seizures, vision and hearing defects, intracranial calcifications, ventriculomegaly and/or lissencephaly (Figure 3) [56]. Symptomatic intrauterine infection may result in severe growth retardation, microcephaly, agyria, hydrocephalus, and multifocal dystrophic calcifications in the cortex and subcortical white matter, with associated cortical displacement and mild focal inflammation [62].

Figure 3.MRI in a Honduran girl of two years and nine months with congenital zika syndrome: T1-weighted (A) axial, and (B) sagittal sections showing a lissencephaly/pachygyria abnormality, ex-vacuo hydrocephalus, and diffuse brain stem and cerebellar atrophy.

Dengue is the most widespread arboviral disease, with an estimated 70–140 million cases occurring annually. There are four genetically and antigenically distinct serotypes of dengue. It is common to see concurrent or sequential infection of multiple serotypes. In 2009, WHO adjustments in the classification of the disease resulted in the recognition of two main disease manifestations: dengue fever and severe dengue [63]. Dengue virus infection causes an acute self-limited febrile syndrome characterised by headache, retro-orbital pain, rash, nausea, vomiting, diarrhoea, myalgia and arthralgia. In individuals with prior exposure to the dengue virus, re-exposure to a different serotype increases severe dengue risk [63]. Severe dengue (formerly called ‘dengue haemorrhagic fever’) is characterised by increased vascular permeability, thrombocytopenia, hemo-concentration, decreased effective circulating blood volume, and haemorrhagic manifestations. Neurological involvement is present in 4–20% of confirmed dengue cases [64]. High body temperature, elevated haematocrit, thrombocytopenia, rash and liver dysfunction are independent risk factors for neurological complications [65]. Neurological manifestations include encephalitis, meningitis, myelitis, and Guillain-Barré syndrome (Table 2). The underlying pathogenesis may include metabolic disturbances resulting in encephalopathy, direct viral invasion, and autoimmune reactions producing optic neuritis, encephalopathy, and GuillainBarré syndrome [66].

Chikungunya virus is a togavirus that is transmitted to humans by the bite of Aedes aegypti or Aedes albopictus mosquitoes. Chikungunya infection was first detected in Southern Tanzania in 1952. The name ‘chikungunya’ in Swahili means ‘that which bends up’ and alludes to the classic clinical symptoms of fever and joint pain. Joint pain can persist for months to years after infection, causing patients to adopt a bent, stooping posture. The infection classically manifests with fever, rash and arthralgia. Though the virus is believed to be neurotropical, the neurological manifestations are poorly described (Table 2) [67]. Neonates with vertically acquired infections may have encephalopathy, white matter lesions, or cerebral oedema or haemorrhage [68].

Encephalitis is the most common neurological symptom and may co-occur within a few days of the onset of systemic symptoms. The virus induces morphometric and innate immune activation of astrocytes in the brain, thus causing them to express high levels of cytokines and chemokines in response to viral infection [69].

The zika, dengue and chikungunya arbovirus infections and their neurological consequences are a major global health problem. Diagnosis is based on clinical, epidemiological and laboratory criteria. Treatment is supportive. Immunologicallymediated disease manifestations are frequently treated with immunomodulatory agents (corticosteroids, intravenous immunoglobulin or plasmapheresis) though no evidence-based recommendations are available.

Clinical trials in tropical infections: challenges and successes

Implementation of clinical trials evaluating interventions for tropical infections can be challenging but may significantly impact public health. Challenges to clinical trial implementation may include a lack of research infrastructure in LMICs where such diseases are prevalent. Fragile supply lines challenge equipment maintenance for clinical care and laboratory studies, mainly when these cross international borders.

With careful planning and development of mitigation strategies, these challenges can eventually be overcome. More challenging is cultural and linguistic barriers. Investigators from HICs may have significant differences from both the populations they are studying and the LMIC collaborators with whom they are working. This may lead to misunderstandings and, if not corrected, a breakdown in the collaborations necessary for clinical trial success. Although attempts to use the local language are often welcomed by local populations, incorrect word use may lead to unintentional offence [70]. Moreover, methods of handling conflict may differ significantly between investigators from HICs and LMICs. Pre-emptive discussion of possible points of disagreement may help avoid conflict. Verbalising expectations from all parties prevent misunderstandings.

Despite these challenges, implementing clinical trials in tropical infections may have significant benefits for HIC investigators and the populations they are studying. Co-investigators from HICs are typically self-selected with a commitment to social justice. LMIC co-investigators are equally self-selected for their work ethic and commitment to the populations with whom they live and work.

Performance of clinical trials in tropical infections may significantly impact populations living in areas where these diseases are found. Tropical infections are common and can lead to mortality (e.g., malaria, viral haemorrhagic fevers, trypanosomiasis) or morbidity (e.g., filariasis). Small effect sizes will have significant health impacts when prevalence is high. Despite the challenges of clinical trial implementation in some LMICs, investigating new therapeutic options for tropical infections is a significant health priority, conferring benefits on both an individual and population level.

Competing interests

None.

Author contributions

All authors have contributed equally to drafting the manuscript and revising it critically for important intellectual content and have given the version’s final approval to be published.

This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.

Cite this article as: Acosta, M. T. et al. (2021). Tropical Infections of the CNS: A worldwide problem Journal of the International Child Neurology Association, 21(1). https://doi.org/10.17724/jicna.2021.224

References

  1. Lozano R, Naghavi M, Foreman K, Lim S, Shibuya K,Aboyans V, et al. Global and regional mortality from 235causes of death for 20 age groups in 1990 and 2010: a sys-tematic analysis for the Global Burden of Disease Study2010. The Lancet. 2012;380(9859):2095-128.PubMed
  2. Singhi P, Saini AG.Fungal and Parasitic CNS Infec-tions. The Indian Journal of Pediatrics. 2017;86(1):83-90.PubMed
  3. Singhi P, Saini AG. Pediatric Neurocysticercosis. The In-dian Journal of Pediatrics. 2017;86(1):76-82.PubMed
  4. Singhi P. Central Nervous System Infections in Children:An Ongoing Challenge! The Indian Journal of Pediatrics. 2018;86(1):49-51.PubMed
  5. Chiang SS, Khan FA, Milstein MB, Tolman AW, BenedettiA, Starke JR, et al. Treatment outcomes of childhood tuber-culous meningitis: a systematic review and meta-analysis.The Lancet Infectious Diseases. 2014;14(10):947-57.PubMed
  6. Thwaites G, Hien T.Tuberculous meningitis: manyquestions, too few answers.The Lancet Neurology. 2005;4(3):160-70.PubMed
  7. Marais S, Thwaites G, Schoeman JF, Török ME, Misra UK,Prasad K, et al. Tuberculous meningitis: a uniform casedefinition for use in clinical research. The Lancet Infectious Diseases. 2010;10(11):803-12.PubMed
  8. Sharawat IK, Saini AG, Vyas S, Sankhyan N. “Encasedbrain” in hypertrophic pachymeningitis. Child's Nervous System. 2019;35(4):585-7.PubMed
  9. Kusum S, Aman S, Pallab R, Kumar SS, Manish M, SudeshP, et al. Multiplex PCR for rapid diagnosis of tuberculousmeningitis. Journal of Neurology. 2011;258(10):1781-7.PubMed
  10. Pormohammad A, Nasiri MJ, McHugh TD, Riahi SM, BahrNC. A Systematic Review and Meta-analysis of the Diag-nostic Accuracy of Nucleic Acid Amplification Tests for Tuberculous Meningitis. Journal of Clinical Microbiology. 2019;57(6).PubMed
  11. Kay AW, Fernández LG, Takwoingi Y, Eisenhut M, Det-jen AK, Steingart KR, et al. Xpert MTB/RIF and XpertMTB/RIF Ultra assays for active tuberculosis and ri-fampicin resistance in children. Cochrane Database of Sys-tematic Reviews. 2020.PubMed
  12. The World Health Organization. WHO, editor. Guid-ance for national tuberculosis programmes on the man-agement of tuberculosis in children – 2nd ed. 2014(WHO/HTM/TB/2014.03). Geneva: World Health Orga-nization; 2021. Date accessed April 1st, 2021. https://www.who.int/publications/i/item/9789241548748.
  13. van Toorn R, Solomons R. Update on the Diagnosis andManagement of Tuberculous Meningitis in Children. Sem-inars in Pediatric Neurology. 2014;21(1):12-8.PubMed
  14. Misra UK, Kalita J, Maurya PK.Stroke in tubercu-lous meningitis.Journal of the Neurological Sciences. 2011;303(1-2):22-30.PubMed
  15. Garg R, Rizvi I, Malhotra H, Kumar N, Uniyal R. Roleof Aspirin in Tuberculous Meningitis: A Systematic Re-view and Meta-analysis. Neurology India. 2019;67(4):993.PubMed
  16. Sharma R, Saini AG, Katoch D, Bhatia V. Never Forgetthe Optic Fundi in Tuberculosis! The Journal of Pediatrics. 2018;195:305.PubMed
  17. Sinha MK, Garg RK, HK A, Agarwal A, Singh MK, VermaR, et al. Vision impairment in tuberculous meningitis: Pre-dictors and prognosis. Journal of the Neurological Sci-ences. 2010;290(1-2):27-32.PubMed
  18. Singanamalla B, Saini AG, Sidana V, Saini L, SankhyanN, Singh P. Progressive quadriparesis and inflammation:A common disease, a rare presentation. Indian Journal ofTuberculosis. 2020;67(3):336-9.PubMed
  19. Saini AG, Verma S, Sodhi KS. Tubercular Dactylitis in aYoung Boy. The Journal of Pediatrics. 2018;195:304-4.e1.PubMed
  20. Kumar A, Gupta D, Nagaraja SB, Singh V, Sethi GR,Prasad J. Updated national guidelines for pediatric tuber-culosis in India, 2012. Indian Pediatrics. 2013;50(3):301-6.PubMed
  21. National Collaborating Centre for Chronic Conditions(UK). Tuberculosis: Clinical Diagnosis and Managementof Tuberculosis, and Measures for Its Prevention and Con-trol. Centre for Clinical Practice at NICE (UK). 2011;1:1-325.PubMed
  22. The World Health Organization. WHO, editor. WHO con-solidated guidelines on drug-resistant tuberculosis treat-ment. Geneva: World Health Organization; 2019. Licence:CC BY-NC-SA 3.0 IGO. https://apps.who.int/iris/handle/10665/311389.
  23. Ettehad D, Schaaf HS, Seddon JA, Cooke GS, Ford N.Treatment outcomes for children with multidrug-resistanttuberculosis: a systematic review and meta-analysis. TheLancet Infectious Diseases. 2012;12(6):449-56.PubMed
  24. Török ME, Bang ND, Chau TTH, Yen NTB, Thwaites GE,Quy HT, et al. Dexamethasone and Long-Term Outcomeof Tuberculous Meningitis in Vietnamese Adults and Ado-lescents. PLoS ONE. 2011;6(12):e27821.PubMed
  25. Marais S, Pepper DJ, Marais BJ, Török ME.HIV-associated tuberculous meningitis – diagnostic and ther-apeutic challenges. Tuberculosis. 2010;90(6):367-74.PubMed
  26. Meintjes G, Stek C, Blumenthal L, Thienemann F, SchutzC, Buyze J, et al. Prednisone for the Prevention of Paradox-ical Tuberculosis-Associated IRIS. New England Journalof Medicine. 2018;379(20):1915-25.PubMed
  27. Keeley AJ, Parkash V, Tunbridge A, Greig J, Collini P,McKane W, et al. Anakinra in the treatment of protractedparadoxical inflammatory reactions in HIV-associated tu-berculosis in the United Kingdom: a report of two cases.International Journal of STD & AIDS.. 2020;31(8):808-12.PubMed
  28. The World Health Organization. WHO, editor. WorldMalaria Report 2018. Geneva: World Health Organiza-tion; 2018. Licence: CC BY-NC-SA 3.0 IGO. https://www.who.int/publications/i/item/9789241548748.
  29. The World Health Organization. Severe malaria. Trop MedInt Health. 2014;19(Suppl. 1):7-131.
  30. Saini AG, Dogra S, Kumar R, and PS.Cervical in-tramedullary conglomerate tuberculomas with tuberculousmeningitis — rapid response to medical therapy.Pae-diatrics and International Child Health. 2012;32(3):171-3.PubMed
  31. Taylor TE, Fu WJ, Carr RA, Whitten RO, Mueller JG, Fos-iko NG, et al. Differentiating the pathologies of cerebralmalaria by postmortem parasite counts. Nature Medicine. 2004;10(2):143-5.PubMed
  32. Barrera V, Hiscott PS, Craig AG, White VA, Milner DA,Beare NAV, et al. Severity of Retinopathy Parallels the De-gree of Parasite Sequestration in the Eyes and Brains ofMalawian Children With Fatal Cerebral Malaria. Journalof Infectious Diseases. 2014;211(12):1977-86.PubMed
  33. Postels DG, Osei-Tutu L, Seydel KB, Xu Q, Li C, Tay-lor TE, et al.Central Nervous System Virus Infec-tion in African Children with Cerebral Malaria.TheAmerican Journal of Tropical Medicine and Hygiene. 2020;103(1):200-5.PubMed
  34. Christensen SS, Eslick GD. Cerebral malaria as a risk fac-tor for the development of epilepsy and other long-termneurological conditions: a meta-analysis.Transactionsof the Royal Society of Tropical Medicine and Hygiene. 2015;109(4):233-8.PubMed
  35. Andronikou S, Smith B, Hatherhill M, Douis H,Wilmshurst J. Definitive neuroradiological diagnostic fea-tures of tuberculous meningitis in children. Pediatric Radi-ology. 2004;34(11):876-85.PubMed
  36. Saini AG, Dogra S, Kumar R, Nada R, Singh M. Pri-mary tuberculous cerebellar abscess: case report. Annalsof Tropical Paediatrics. 2011;31(4):367-9.PubMed
  37. Donovan J, Cresswell FV, Thuong NTT, Boulware DR,Thwaites GE, Bahr NC, et al. Xpert MTB/RIF Ultra forthe Diagnosis of Tuberculous Meningitis: A Small StepForward. Clinical Infectious Diseases. 2020;71(8):2002-5.PubMed
  38. Cresswell FV, Tugume L, Bahr NC, Kwizera R, Bangdi-wala AS, Musubire AK, et al. Xpert MTB/RIF Ultra forthe diagnosis of HIV-associated tuberculous meningitis: aprospective validation study. The Lancet Infectious Dis-eases. 2020;20(3):308-17.PubMed
  39. Pai M, Flores LL, Pai N, Hubbard A, Riley LW, ColfordJM. Diagnostic accuracy of nucleic acid amplification testsfor tuberculous meningitis: a systematic review and meta-analysis. The Lancet Infectious Diseases. 2003;3(10):633-43.PubMed
  40. Agarwal S, Saini AG, Dhawan S, Khadwal A, Sharma K,Singhi P. Comparative evaluation of IS6110 and proteinantigen b PCR in cerebrospinal fluid for rapid diagnosisof tuberculous meningitis in children. Journal of MedicalMicrobiology. 2020;69(7):979-85.PubMed
  41. Sinclair D, Donegan S, Isba R, Lalloo DG. Artesunate ver-sus quinine for treating severe malaria. Cochrane Databaseof Systematic Reviews. 2012.PubMed
  42. Idro R, Jenkins NE, Newton CR. Pathogenesis, clinical fea-tures, and neurological outcome of cerebral malaria. The Lancet Neurology. 2005;4(12):827-40.PubMed
  43. Crawley J, Waruiru C, Mithwani S, Mwangi I, WatkinsW, Ouma D, et al.Effect of phenobarbital on seizurefrequency and mortality in childhood cerebral malaria: arandomised, controlled intervention study. The Lancet. 2000;355(9205):701-6.PubMed
  44. Gwer SA, Idro RI, Fegan G, Chengo EM, Mpoya A, KivayaE, et al. Fosphenytoin for seizure prevention in childhoodcoma in Africa: A randomized clinical trial. Journal of Critical Care. 2013;28(6):1086-92.PubMed
  45. Birbeck GL, Herman ST, Capparelli EV, Dzinjalamala FK,Baki SGA, Mallewa M, et al. A clinical trial of enteral Lev-etiracetam for acute seizures in pediatric cerebral malaria. BMC Pediatrics. 2019;19(1)..PubMed
  46. Enwere G. A review of the quality of randomized clini-cal trials of adjunctive therapy for the treatment of cere-bral malaria. Tropical Medicine and International Health. 2005;10(11):1171-5.PubMed
  47. Seydel KB, Kampondeni SD, Valim C, Potchen MJ, Mil-ner DA, Muwalo FW, et al. Brain Swelling and Death inChildren with Cerebral Malaria. New England Journal of Medicine. 2015;372(12):1126-37.PubMed
  48. Mousa A, Al-Taiar A, Anstey NM, Badaut C, Barber BE,Bassat Q, et al. The impact of delayed treatment of un-complicated P. falciparum malaria on progression to se-vere malaria: A systematic review and a pooled multi-centre individual-patient meta-analysis. PLOS Medicine. 2020;17(10):e1003359.PubMed
  49. State of the Tropics. State of the Tropics, ed-itor. State of the Tropics 2020 Report. James Cook University, Townsville, Australia; 2020. https://www.jcu.edu.au/state-of-the-tropics/publications/state-of-the-tropics-2020-report.
  50. Medina MT, Meshram C, England J, Shakir R. TropicalNeurology Education: A World Federation of Neurologyoutstanding priority. Journal of the Neurological Sciences. 2021;421:117281.PubMed
  51. Beckham JD, Tyler KL. Arbovirus Infections. CONTIN-UUM: Lifelong Learning in Neurology.. 2015;21:1599-611.PubMed
  52. Peltier DC, Lazear HM, Farmer JR, Diamond MS, MillerDJ. Neurotropic Arboviruses Induce Interferon RegulatoryFactor 3-Mediated Neuronal Responses That Are Cytopro-tective, Interferon Independent, and Inhibited by WesternEquine Encephalitis Virus Capsid. Journal of Virology. 2012;87(3):1821-33.PubMed
  53. Dick GWA, Kitchen SF, Haddow AJ.Zika Virus (I).Isolations and serological specificity.Transactions ofthe Royal Society of Tropical Medicine and Hygiene. 1952;46(5):509-20.PubMed
  54. Duffy MR, Chen TH, Hancock WT, Powers AM, Kool JL,Lanciotti RS, et al. Zika Virus Outbreak on Yap Island,Federated States of Micronesia. New England Journal ofMedicine. 2009;360(24):2536-43.PubMed
  55. Cao-Lormeau VM, Blake A, Mons S, Lastère S, Roche C, Vanhomwegen J, et al. Guillain-Barré Syndrome outbreakassociated with Zika virus infection in French Polynesia: acase-control study. The Lancet. 2016;387(10027):1531-9.PubMed
  56. de Barros Miranda-Filho D, Martelli CMT, de Alen-car Ximenes RA, Araújo TVB, Rocha MAW, Ramos RCF,et al. Initial Description of the Presumed Congenital Zika Syndrome. American Journal of Public Health. 2016;106(4):598-600.PubMed
  57. Aragao MFVV, Holanda AC, Brainer-Lima AM, PetribuNCL, Castillo M, van der Linden V, et al. Nonmicro-cephalic Infants with Congenital Zika Syndrome SuspectedOnly after Neuroimaging Evaluation Compared with Thosewith Microcephaly at Birth and Postnatally: How Large Isthe Zika Virus “Iceberg”? American Journal of Neuroradi-ology. 2017;38(7):1427-34.PubMed
  58. Lebov JF, Arias JF, Balmaseda A, Britt W, Cordero JF,Galvão LA, et al.International prospective observa-tional cohort study of Zika in infants and pregnancy (ZIPstudy): study protocol. BMC Pregnancy and Childbirth. 2019;19(1).PubMed
  59. Medina MT, Medina-Montoya M. New spectrum of theneurologic consequences of Zika. Journal of the Neurolog-ical Sciences. 2017;383:214-5.PubMed
  60. Oh Y, Zhang F, Wang Y, Lee EM, Choi IY, Lim H, et al.Zika virus directly infects peripheral neurons and inducescell death.Nature Neuroscience. 2017;20(9):1209-12.PubMed
  61. McGrath EL, Rossi SL, Gao J, Widen SG, Grant AC, DunnTJ, et al. Differential Responses of Human Fetal BrainNeural Stem Cells to Zika Virus Infection. Stem Cell Re-ports. 2017;8(3):715-27.PubMed
  62. Mlakar J, Korva M, Tul N, Popovi ́c M, Poljšak-Prijatelj M,Mraz J, et al. Zika Virus Associated with Microcephaly.New England Journal of Medicine. 2016;374(10):951-8.PubMed
  63. The World Health Organization. World Health Organiza-tion and Special Programme for Research and Trainingin Tropical Diseases, 2009, editor. Dengue: Guidelinesfor diagnosis, treatment, prevention and control. Geneva:World Health Organization; 2021. https://apps.who.int/iris/handle/10665/44188.
  64. Puccioni-Sohler M, Soares CN, Papaiz-Alvarenga R, Cas-tro MJC, Faria LC, Peralta JM. Neurologic dengue man-ifestations associated with intrathecal specific immune re-sponse. Neurology. 2009;73(17):1413-7.PubMed
  65. Sahu R, Verma R, Jain A, Garg RK, Singh MK, Mal-hotra HS, et al.Neurologic complications in denguevirus infection: A prospective cohort study. Neurology.. 2014;83(18):1601-9.PubMed
  66. Murthy JMK. Neurological complication of dengue infec-tion. Neurology India. 2010;58(4):581.PubMed
  67. Samra JA, Hagood NL, Summer A, Medina MT, HoldenKR. Clinical Features and Neurologic Complications ofChildren Hospitalized With Chikungunya Virus in Hon-duras.Journal of Child Neurology. 2017;32(8):712-6.PubMed
  68. Das T, Jaffar-Bandjee MC, Hoarau JJ, Trotot PK, DenizotM, Lee-Pat-Yuen G, et al. Chikungunya fever: CNS infec-tion and pathologies of a re-emerging arbovirus. Progressin Neurobiology. 2010;91(2):121-9.PubMed
  69. Inglis FM, Lee KM, Chiu KB, Purcell OM, Didier PJ,Russell-Lodrigue K, et al. Neuropathogenesis of Chikun-gunya infection: astrogliosis and innate immune activation.Journal of NeuroVirology. 2015;22(2):140-8.PubMed
  70. Azuine R. Overcoming Challenges in Conducting Clini-cal Trials in Minority Populations: Identifying and Test-ing What Works. International Journal of MCH and AIDS(IJMA). 2014;3(1).PubMed

Main Article Content

Abstract

Neuroinfectious diseases continue to have a profound public health impact, particularly in resource-limited settings. Here we summarize the new research into pathophysiology, diagnosis, and treatment modalities for some of the most frequent and lethal infections affecting the central nervous system, including tuberculosis, malaria, and arboviral infections. Implementation of clinical trials targeting neuroinfectious diseases in resource-limited settings has unique challenges not found when identical research is performed in resource-rich areas. Travel, communications, and technology have improved the mobility of populations worldwide. Immigration and increased international travel make it likely that clinicians worldwide will see patients affected by infectious diseases such as malaria, tuberculosis, zika, dengue, chikungunya, and Ebola. Such infections may have devastating consequences for both the individual and the society, particularly if clinicians are not familiar with disease presentation and treatment.

Keywords

Keywords: CNS infection; Malaria; Tuberculosis; Zika; Dengue; Chikungunya; Clinical trials

Article Details

Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.

How to Cite
Acosta, M. ., Saini, A. G., Postels, D. ., Medina, M., Cerisola, A. ., & Singhi , P. . (2021). Tropical Infections of the CNS: A worldwide problem: Tropical CNS Infections. Journal of the International Child Neurology Association, 1(1). https://doi.org/10.17724/jicna.2021.224
Download Citation
Endnote/Zotero/Mendeley (RIS)
BibTeX

References

    1. Lozano R, Naghavi M, Foreman K, Lim S, Shibuya K, Aboyans V, et al. Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet. 2012;380(9859):2095-128.
    2. Singhi P, Saini AG. Fungal and Parasitic CNS Infections. Indian J Pediatr. 2019;86(1):83-90.
    3. Singhi P, Saini AG. Pediatric Neurocysticercosis. Indian J Pediatr. 2019;86(1):76-82.
    4. Singhi P. Central Nervous System Infections in Children: An Ongoing Challenge! Indian J Pediatr. 2019;86(1):49-51.
    5. Chiang SS, Khan FA, Milstein MB, Tolman AW, Benedetti A, Starke JR, et al. Treatment outcomes of childhood tuberculous meningitis: a systematic review and meta-analysis. Lancet Infect Dis. 2014;14(10):947-57.
    6. Thwaites GE, Tran TH. Tuberculous meningitis: many questions, too few answers. Lancet Neurol. 2005;4(3):160-70.
    7. Marais S, Thwaites G, Schoeman JF, Torok ME, Misra UK, Prasad K, et al. Tuberculous meningitis: a uniform case definition for use in clinical research. Lancet Infect Dis. 2010;10(11):803-12.
    8. Sharawat IK, Saini AG, Vyas S, Sankhyan N. "Encased brain" in hypertrophic pachymeningitis. Childs Nerv Syst. 2019;35(4):585-7.
    9. Kusum S, Aman S, Pallab R, Kumar SS, Manish M, Sudesh P, et al. Multiplex PCR for rapid diagnosis of tuberculous meningitis. J Neurol. 2011;258(10):1781-7.
    10. Pormohammad A, Nasiri MJ, McHugh TD, Riahi SM, Bahr NC. A Systematic Review and Meta-analysis of the Diagnostic Accuracy of Nucleic Acid Amplification Tests for Tuberculous Meningitis. J Clin Microbiol. 2019;57(6).
    11. Kay AW, Gonzalez Fernandez L, Takwoingi Y, Eisenhut M, Detjen AK, Steingart KR, et al. Xpert MTB/RIF and Xpert MTB/RIF Ultra assays for active tuberculosis and rifampicin resistance in children. Cochrane Database Syst Rev. 2020;8:CD013359.
    12. Guidance for national tuberculosis programmes on the management of tuberculosis in children – 2nd ed. 2014.
    13. van Toorn R, Solomons R. Update on the diagnosis and management of tuberculous meningitis in children. Semin Pediatr Neurol. 2014;21(1):12-8.
    14. Misra UK, Kalita J, Maurya PK. Stroke in tuberculous meningitis. J Neurol Sci. 2011;303(1-2):22-30.
    15. Rizvi I, Garg RK, Malhotra HS, Kumar N, Uniyal R. Role of Aspirin in Tuberculous Meningitis: A Systematic Review and Meta-analysis. Neurol India. 2019;67(4):993-1002.
    16. Sharma R, Saini AG, Katoch D, Bhatia V. Never Forget the Optic Fundi in Tuberculosis! J Pediatr. 2018;195:305.
    17. Sinha MK, Garg RK, Anuradha H, Agarwal A, Singh MK, Verma R, et al. Vision impairment in tuberculous meningitis: predictors and prognosis. J Neurol Sci. 2010;290(1-2):27-32.
    18. Singanamalla B, Saini AG, Sidana V, Saini L, Sankhyan N, Singh P. Progressive quadriparesis and inflammation: A common disease, a rare presentation. Indian J Tuberc. 2020;67(3):336-9.
    19. Saini AG, Verma S, Sodhi KS. Tubercular Dactylitis in a Young Boy. J Pediatr. 2018;195:304- e1.
    20. Kumar A, Gupta D, Nagaraja SB, Singh V, Sethi GR, Prasad J, et al. Updated national guidelines for pediatric tuberculosis in India, 2012. Indian Pediatr. 2013;50(3):301-6.
    21. National Collaborating Centre for Chronic Conditions (UK); Centre for Clinical Practice at NICE (UK). Tuberculosis: Clinical Diagnosis and Management of Tuberculosis, and Measures for Its Prevention and Control. London: National Institute for Health and Clinical Excellence (UK); 2011 Mar. PMID: 22720337.
    22. WHO consolidated guidelines on drug-resistant tuberculosis treatment. Geneva: World Health Organization; 2019.
    Licence: CC BY-NC-SA 3.0 IGO.
    23. Ettehad D, Schaaf HS, Seddon JA, Cooke GS, Ford N. Treatment outcomes for children with multidrug-resistant tuberculosis: a systematic review and meta-analysis. Lancet Infect Dis. 2012;12(6):449-56.
    24. Torok ME, Nguyen DB, Tran TH, Nguyen TB, Thwaites GE, Hoang TQ, et al. Dexamethasone and long-term outcome of tuberculous meningitis in Vietnamese adults and adolescents. PLoS One. 2011;6(12):e27821.
    25. Marais S, Pepper DJ, Marais BJ, Torok ME. HIV-associated tuberculous meningitis--diagnostic and therapeutic challenges. Tuberculosis (Edinb). 2010;90(6):367-74.
    26. Meintjes G, Stek C, Blumenthal L, Thienemann F, Schutz C, Buyze J, et al. Prednisone for the Prevention of Paradoxical Tuberculosis-Associated IRIS. The New England journal of medicine. 2018;379(20):1915-25.
    27. Keeley AJ, Parkash V, Tunbridge A, Greig J, Collini P, McKane W, et al. Anakinra in the treatment of protracted paradoxical inflammatory reactions in HIV-associated tuberculosis in the United Kingdom: a report of two cases. Int J STD AIDS. 2020;31(8):808-12.
    28. Thwaites GE, van Toorn R, Schoeman J. Tuberculous meningitis: more questions, still too few answers. Lancet Neurol. 2013;12(10):999-1010.
    29. Andronikou S, Smith B, Hatherhill M, Douis H, Wilmshurst J. Definitive neuroradiological diagnostic features of tuberculous meningitis in children. Pediatr Radiol. 2004;34(11):876-85.
    30. Saini AG, Dogra S, Kumar R, Nada R, Singh M. Primary tuberculous cerebellar abscess: case report. Ann Trop Paediatr. 2011;31(4):367-9.
    31. Saini AG, Dogra S, Devidayal, Kumar R, Singh P. Cervical intramedullary conglomerate tuberculomas with tuberculous meningitis--rapid response to medical therapy. Paediatr Int Child Health. 2012;32(3):171-3.
    32. Donovan J, Cresswell FV, Thuong NTT, Boulware DR, Thwaites GE, Bahr NC, et al. Xpert MTB/RIF Ultra for the Diagnosis of Tuberculous Meningitis: A Small Step Forward. Clin Infect Dis. 2020;71(8):2002-5.
    33. Cresswell FV, Tugume L, Bahr NC, Kwizera R, Bangdiwala AS, Musubire AK, et al. Xpert MTB/RIF Ultra for the diagnosis of HIV-associated tuberculous meningitis: a prospective validation study. Lancet Infect Dis. 2020;20(3):308-17.
    34. Pai M, Flores LL, Pai N, Hubbard A, Riley LW, Colford JM, Jr. Diagnostic accuracy of nucleic acid amplification tests for tuberculous meningitis: a systematic review and meta-analysis. Lancet Infect Dis. 2003;3(10):633-43.
    35. Agarwal S, Saini AG, Dhawan S, Khadwal A, Sharma K, Singhi P. Comparative evaluation of IS6110 and protein antigen b PCR in cerebrospinal fluid for rapid diagnosis of tuberculous meningitis in children. J Med Microbiol. 2020;69(7):979-85.
    36. Tuon FF, Higashino HR, Lopes MI, Litvoc MN, Atomiya AN, Antonangelo L, et al. Adenosine deaminase and tuberculous meningitis--a systematic review with meta-analysis. Scand J Infect Dis. 2010;42(3):198-207.
    37. World Malaria Report 2018. Geneva: World Health Organization; 2018. Licence: CC BY-NC-SA 3.0 IGO.
    38. Severe malaria. Trop Med Int Health. 2014;19 Suppl 1:7-131.
    39. Saini A DS, Devidayal, Nada R, Ramachandran R, Doraiswamy A. Glomerular thrombotic microangiopathy caused by Plasmodium vivax infection. Journal of Pediatric Sciences ; . 2012;4:e123.
    40. Taylor TE, Fu WJ, Carr RA, Whitten RO, Mueller JS, Fosiko NG, et al. Differentiating the pathologies of cerebral malaria by postmortem parasite counts. Nat Med. 2004;10(2):143-5.
    41. Barrera V, Hiscott PS, Craig AG, White VA, Milner DA, Beare NA, et al. Severity of retinopathy parallels the degree of parasite sequestration in the eyes and brains of malawian children with fatal cerebral malaria. J Infect Dis. 2015;211(12):1977-86.
    42. Postels DG, Osei-Tutu L, Seydel KB, Xu Q, Li C, Taylor TE, et al. Central Nervous System Virus Infection in African Children with Cerebral Malaria. Am J Trop Med Hyg. 2020;103(1):200-5.
    43. Christensen SS, Eslick GD. Cerebral malaria as a risk factor for the development of epilepsy and other long-term neurological conditions: a meta-analysis. Transactions of the Royal Society of Tropical Medicine and Hygiene. 2015;109(4):233-8.
    44. Sinclair D, Donegan S, Isba R, Lalloo DG. Artesunate versus quinine for treating severe malaria. Cochrane Database Syst Rev. 2012(6):CD005967.
    45. Idro R, Jenkins NE, Newton CR. Pathogenesis, clinical features, and neurological outcome of cerebral malaria. Lancet Neurol. 2005;4(12):827-40.
    46. Crawley J, Waruiru C, Mithwani S, Mwangi I, Watkins W, Ouma D, et al. Effect of phenobarbital on seizure frequency and mortality in childhood cerebral malaria: a randomised, controlled intervention study. Lancet. 2000;355(9205):701-6.
    47. Gwer SA, Idro RI, Fegan G, Chengo EM, Mpoya A, Kivaya E, et al. Fosphenytoin for seizure prevention in childhood coma in Africa: a randomized clinical trial. J Crit Care. 2013;28(6):1086-92.
    48. Birbeck GL, Herman ST, Capparelli EV, Dzinjalamala FK, Abdel Baki SG, Mallewa M, et al. A clinical trial of enteral Levetiracetam for acute seizures in pediatric cerebral malaria. BMC pediatrics. 2019;19(1):399.
    49. Enwere G. A review of the quality of randomized clinical trials of adjunctive therapy for the treatment of cerebral malaria. Trop Med Int Health. 2005;10(11):1171-5.
    50. Seydel KB, Kampondeni SD, Valim C, Potchen MJ, Milner DA, Muwalo FW, et al. Brain swelling and death in children with cerebral malaria. The New England journal of medicine. 2015;372(12):1126-37.
    51. Mousa A, Al-Taiar A, Anstey NM, Badaut C, Barber BE, Bassat Q, et al. The impact of delayed treatment of uncomplicated P. falciparum malaria on progression to severe malaria: A systematic review and a pooled multicentre individual-patient meta-analysis. PLoS Med. 2020;17(10):e1003359.
    52. State of the Tropics (2020) State of the Tropics 2020 Report. James Cook University, Townsville, Australia. .
    53. Medina M, Meshram C, England J. Tropical Neurology Education: a World Federation of Neurology outstanding priority J Neurol Sciences In Press. 2020.
    54. Beckham JD, Tyler KL. Arbovirus Infections. Continuum (Minneap Minn). 2015;21(6 Neuroinfectious Disease):1599-611.
    55. Peltier DC, Lazear HM, Farmer JR, Diamond MS, Miller DJ. Neurotropic arboviruses induce interferon regulatory factor 3-mediated neuronal responses that are cytoprotective, interferon independent, and inhibited by Western equine encephalitis virus capsid. J Virol. 2013;87(3):1821-33.
    56. Dick GW, Kitchen SF, Haddow AJ. Zika virus. I. Isolations and serological specificity. Transactions of the Royal Society of Tropical Medicine and Hygiene. 1952;46(5):509-20.
    57. Duffy MR, Chen TH, Hancock WT, Powers AM, Kool JL, Lanciotti RS, et al. Zika virus outbreak on Yap Island, Federated States of Micronesia. The New England journal of medicine. 2009;360(24):2536-43.
    58. Cao-Lormeau VM, Blake A, Mons S, Lastere S, Roche C, Vanhomwegen J, et al. Guillain-Barre Syndrome outbreak associated with Zika virus infection in French Polynesia: a case-control study. Lancet. 2016;387(10027):1531-9.
    59. Miranda-Filho Dde B, Martelli CM, Ximenes RA, Araujo TV, Rocha MA, Ramos RC, et al. Initial Description of the Presumed Congenital Zika Syndrome. Am J Public Health. 2016;106(4):598-600.
    60. Aragao M, Holanda AC, Brainer-Lima AM, Petribu NCL, Castillo M, van der Linden V, et al. Nonmicrocephalic Infants with Congenital Zika Syndrome Suspected Only after Neuroimaging Evaluation Compared with Those with Microcephaly at Birth and Postnatally: How Large Is the Zika Virus "Iceberg"? AJNR Am J Neuroradiol. 2017;38(7):1427-34.
    61. Lebov JF, Arias JF, Balmaseda A, Britt W, Cordero JF, Galvao LA, et al. International prospective observational cohort study of Zika in infants and pregnancy (ZIP study): study protocol. BMC Pregnancy Childbirth. 2019;19(1):282.
    62. Medina MT, Medina-Montoya M. New spectrum of the neurologic consequences of Zika. J Neurol Sci. 2017;383:214-5.
    63. Oh Y, Zhang F, Wang Y, Lee EM, Choi IY, Lim H, et al. Zika virus directly infects peripheral neurons and induces cell death. Nat Neurosci. 2017;20(9):1209-12.
    64. McGrath EL, Rossi SL, Gao J, Widen SG, Grant AC, Dunn TJ, et al. Differential Responses of Human Fetal Brain Neural Stem Cells to Zika Virus Infection. Stem Cell Reports. 2017;8(3):715-27.
    65. Mlakar J, Korva M, Tul N, Popovic M, Poljsak-Prijatelj M, Mraz J, et al. Zika Virus Associated with Microcephaly. The New England journal of medicine. 2016;374(10):951-8.
    66. WHO Dengue: Guidelines for diagnosis, treatment, prevention and control. World Health Organization and Special Programme for Research and Training in Tropical Diseases, 2009. .
    67. Puccioni-Sohler M, Soares CN, Papaiz-Alvarenga R, Castro MJ, Faria LC, Peralta JM. Neurologic dengue manifestations associated with intrathecal specific immune response. Neurology. 2009;73(17):1413-7.
    68. Sahu R, Verma R, Jain A, Garg RK, Singh MK, Malhotra HS, et al. Neurologic complications in dengue virus infection: a prospective cohort study. Neurology. 2014;83(18):1601-9.
    69. Murthy JM. Neurological complication of dengue infection. Neurol India. 2010;58(4):581-4.
    70. Samra JA, Hagood NL, Summer A, Medina MT, Holden KR. Clinical Features and Neurologic Complications of Children Hospitalized With Chikungunya Virus in Honduras. J Child Neurol. 2017;32(8):712-6.
    71. Das T, Jaffar-Bandjee MC, Hoarau JJ, Krejbich Trotot P, Denizot M, Lee-Pat-Yuen G, et al. Chikungunya fever: CNS infection and pathologies of a re-emerging arbovirus. Prog Neurobiol. 2010;91(2):121-9.
    72. Inglis FM, Lee KM, Chiu KB, Purcell OM, Didier PJ, Russell-Lodrigue K, et al. Neuropathogenesis of Chikungunya infection: astrogliosis and innate immune activation. J Neurovirol. 2016;22(2):140-8.
    73. Azuine RE, Ekejiuba SE. Overcoming Challenges in Conducting Clinical Trials in Minority Populations: Identifying and Testing What Works. Int J MCH AIDS. 2015;3(1):81-4.